About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, November 3rd, 2014

The QualityStocks
Daily Stock List


Sunvalley Solar, Inc. (SSOL)

Wallstreetlivechat, Fast Moving Stocks, The Stock Scout, PennyStockClub, PennyStocks24, Penny Stock Rumble, Penny Stock Pros, Liquid Pennies, and HEROSTOCKS, VIP STOCK ALERTS and Stockhunter.us reported previously on Sunvalley Solar, Inc. (SSOL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in January 2007, Sunvalley Solar, Inc. is a solar power technology and system integration enterprise that lists on the OTCQB. The Company provides comprehensive solar energy technology, system design, installation, equipments, and technical support for electrical contractors, builders, homeowners, government entities, and businesses/commercial buildings. It offers an all-in-one service for customers' solar system needs. This is from system design and permitting, to installation and final inspection.

The Company’s Research and Development (R&D) team consists of PhDs in Optoelectronics. The team specializes in photovoltaic panel technologies (coating and focusing). Sunvalley Solar has its corporate headquarters in Los Angeles, California.

Sunvalley Solar is a leading solar electric equipment wholesale distributor for solar photovoltaic equipment of manufacturers. It specializes in packaged solar system solutions. Its emphasis is Solar System Design and Installation, Solar Equipment Distribution, Solar Technology Research and Development, and as a National Solar Technical Support and Service Center.

The Company’s growth strategy includes developing and commercializing its proprietary solar technologies. This includes its coating and focusing technologies, racking, and panel cleaning system. Furthermore, Sunvalley Solar’s growth strategy includes promoting and enhancing its brand and reputation in solar design and integration and expanding its installation business, and developing a PV panel manufacturing capability to provide high efficiency and low cost solar panels to the U.S. market. Additionally, the Company’s emphasis is getting involved in the private power providing business (Distributed Power Plants).

Sunvalley Solar’s R&D team involves in advanced solar technologies research, development, and commercialization. This team’s experience includes residential, small commercial, and complex large commercial solar system integration projects. Its projects include 975 kW commercial solar power systems for distribution warehouses and manufacturing companies, and 1 MW commercial solar power systems for agriculture farms and cold storage facilities.

Sunvalley Solar announced this past June that it was awarded a new 676.5 KW solar system installation contract for Raven Farms in Selma, California. When completed, the system will generate more than 1.1 million kWh of clean energy to offset 75 percent of the facility's electric bill. The expectation is that the system will pay for itself in approximately four years and decrease the plant's carbon footprint by over 1.6 million pounds of CO2 each year.

Sunvalley Solar is planning to expand its installation business. The Company will continue to execute its marketing and sales strategy in Southern California and, with added capital, will be able to expand its business to cover Northern California, Arizona or other states. The expectation is that the planned expansion will occur through acquiring smaller installation companies in these regions and/or via the formation of subsidiaries in these states and boost the Company’s installation profits. Sunvalley Solar’s present intention is to establish two new offices located in Northern California or other states and in San Diego, California.

Sunvalley Solar, Inc. (SSOL), closed Monday's trading session at $0.014, even for the day, on 347,264 volume with 14 trades. The average volume for the last 60 days is 135,532 and the stock's 52-week low/high is $0.01/$0.041.

Breitling Energy Corp. (BECC)

BUYINS.NET reported earlier on Breitling Energy Corp. (BECC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Breitling Energy Corp. is an oil and gas exploration and production company with corporate headquarters in Dallas, Texas. The Company acquires and develops lower risk onshore oil and gas working interests and royalty interests in proven basins in the United States. Bering Exploration, Inc. announced on January 22, 2014, that it changed its name to Breitling Energy Corp.  Founded in 2004, Breitling Energy’s shares trade on the OTCQB.

On December 9, 2013, Bering Exploration and Breitling Oil and Gas, together with Breitling Royalties Corp. (collectively, Breitling) jointly announced that the Company and Breitling entered into an Asset Purchase Agreement where the Company issued to Breitling approximately 461.9 million shares of common stock in exchange for largely all of the oil and gas assets owned by Breitling.

Breitling Energy’s oil and gas operations are centered principally in the Permian Basin of Texas and the Mississippi oil window of southern Kansas. The Company has non-operating investments in Texas, North Dakota, Oklahoma, as well as Mississippi. The Company’s operating areas are exemplified by long-lived natural gas and oil reserves and established production capabilities with abundant growth opportunities.

Breitling Energy announced this past September that the second well under the Company’s Farmout Agreement in Sterling County Texas, reached an approximate total depth of 9,000 feet. The Hoppe '63' #1 was spudded September 12, 2014. Breitling reported that the well encountered the same productive formations as in its initial Sterling County well, the Parramore #1. The Company’s plan is to drill eight wells on its Sterling County property to earn the total acreage under the Farmout Agreement.

Breitling Energy’s Buresh 17-#1HM well in Sumner County, Kansas went online on September 11, 2014, producing roughly 127 barrels of oil and a substantial amount of flowback water during the first 12 hours. The well's oil production has continued to grow. It is now approaching 300 barrels a day. In the first 12 days, the well produced around 3,000 total barrels of oil.

Last month, Breitling Energy reported that it continues to move ahead with the upcoming completion of its second Permian Basin well (Hoppe "63" #1 in Sterling County, Texas). The well reached a total depth of approximately 8,600 ft. in the Lower Strawn on September 24, 2014. It was logged on the following day. Physical hydrocarbon shows and oil indicators on the logs were present in numerous formations. These include the Middle Wolfcamp Lime, the Albaugh Lime, the Triple "M" Lime, Credo Lime, Cisco sands, Canyon "B" and "C" sands, the Cline sandy shale as well as in the Strawn Lime.

Breitling Energy Corp. (BECC), closed Monday's trading session at $0.50, even for the day, on 19,335 volume with 14 trades. The average volume for the last 60 days is 47,822 and the stock's 52-week low/high is $0.051/$0.95.

AmpliPhi Biosciences Corp. (APHB)

Wallstreetlivechat and StreetInsider reported earlier on AmpliPhi Biosciences Corp. (APHB), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

AmpliPhi Biosciences Corp. is a biotechnology company and the international leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections. The Company’s product development programs target infections, which are often resistant to existing antibiotic treatments. OTCQB-listed AmpliPhi Biosciences has its headquarters in Richmond, Virginia. It has operations in Ljubljana, Slovenia and Sydney, Australia.

The Company focuses on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Bacteriophages, or “eaters of bacteria,” are highly targeted viruses. They only infect bacteria. As they grow, many bacteriophages destroy their bacterial host to release hundreds of new bacteriophages. 

Phage-based therapy provides an inventive and proven approach to treating a wide array of bacterial infections and more precisely, drug-resistant strains of bacteria that are generally found in hospitals. AmpliPhi Biosciences is the first company to demonstrate the clinical efficacy of phage technology in a controlled, regulated, human clinical trial. The Company has focused initially on controlling one particular problem, namely “Pseudomonas aeruginosa infections. Pseudomonas aeruginosa is a common soil organism. It is responsible for long-term problems in humans, infecting burns, wounds, and body cavities.

AmpliPhi Biosciences is working together with a number of leading organizations to quickly advance bacteriophage-based therapies. These organizations include Intrexon Corp. (XON), the U.S. Army, as well as UK-based University of Leicester. AmpliPhi’s proprietary technology has additional applications for the treatment of a broad variety of serious infections.

The Company’s product development pathway includes AmpliPhage-001: Lung Infections in Cystic Fibrosis (CF) Patients Caused by P. aeruginosa; AmpliPhage-002: Wound and Skin Infections Caused by S. aureus; and AmpliPhage-004; Gastrointestinal (GI) Infection Caused by C. difficile infection (CDI).

Recently, AmpliPhi Biosciences announced that it continues to concentrate on ongoing strategic research and development initiatives with leading industry, academic, and government partners in Europe, Australia, and the United States. It also remains focused on establishing a dedicated cGMP (current Good Manufacturing Practices) bacteriophage manufacturing facility.

AmpliPhi Biosciences Corp. (APHB), closed Monday's trading session at $0.18, down 2.70%, on 30,200 volume with 10 trades. The average volume for the last 60 days is 161,144 and the stock's 52-week low/high is $0.07/$0.74.

Validian Corp. (VLDI)

Profit Sensation, Pumps and Dumps, PennyStocks24, and OTC Stock Review reported earlier on Validian Corp. (VLDI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Atlanta, Georgia, Validian Corp. provides software products for public and private enterprises. The Company develops and markets solutions to protect against the threats of today's digital world. It is first-to-market to provide secure storage, access and transfer of Digital Information on wired, wireless or mobile networks over the Internet. Validian’s mission is to deliver creative information protection solutions, which help government agencies, enterprises, and individuals reduce the impact of theft, disclosure, non-compliance, or malicious tampering with digital assets. Validian’s shares trade on the OTCQB.

Validian offers solutions, which can undergo customization to the client's business process to ensure end-to-end authenticity, integrity, and custody of high value digital assets. Its technology enables the next generation of secure Cloud Computing, Cloud Storage, Distributed Computing and Web Application and WebPortal Access and Usage for desktop and laptop computers, servers, tablets, and SmartPhones.

The Company’s products include ValidianProtect, which embeds its technology into any application. Another product is Validian Media Protect. This is an anti-piracy solution. Validian Media Protect safeguards high-value movie and music content during production and post-production.

Validian also has its Validian Medical Protect. This provides secure remote access and exchange of any kind of medical file between medical professionals. In addition, the Company’s products include Validian Secure Microsoft SharePoint. It allows secure content management and web portals. Products also include Validian Mobile, which enables secure e-commerce transactions over non-compatible Smartphone devices, cell sites, as well as networks.

Validian announced recently that it entered into collaboration with a channel partner to complete the integration of its core, disruptive top-down cyber security technology platform, ValidianProtect version 2.1, into its ShareProtect secure file transfer application. This provides the first-ever solution to secure access to, and transfer of, confidential digital information and data. Validian’s channel partner provides solutions to the professional, financial, and government sectors.

Last month, Validian announced that the Company is now working with a new channel partner, a provider of solutions to Telecoms, Mobile Network Operators, and direct to consumer and enterprise end users. This is to bring a fully secure Mobile Messaging App based on Validian's cyber security technology to the market. Validian is targeting its release in this fourth quarter of 2014. 

Validian Corp. (VLDI), closed Monday's trading session at $0.0356, down 17.21%, on 333,200 volume with 12 trades. The average volume for the last 60 days is 559,897 and the stock's 52-week low/high is $0.0212/$0.105.

Praxsyn Corp. (PXYN)

OtcShortReport, Pennystocktweeters.com, Impressive Penny Stocks, OTCMagic, Winston Small Cap, Penny Stock Circle, and Bull Trends reported recently on Praxsyn Corp. (PXYN), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Founded in 2005, OTCQB-listed Praxsyn Corp. concentrates on providing custom compounded non-narcotic, transdermal topical pain medications to industrial health physicians and clinics. At present, the Company formulates transdermal creams in its compounding pharmacy, Mesa Pharmacy. It has developed a series of topical ointments for pain relief. Headquartered in Irvine, California, the Company was formerly known as The PAWS Pet Company, Inc. It changed its name to Praxsyn Corp. in March 2014.

Praxsyn is working on establishing its Point of Care/In-Office Dispensing Program, and its’ In-Office Toxicology Testing. The Company’s Point-Of-Care Services will provide the health care provider with pharmaceuticals and testing services, which are convenient and easy for physicians and staff.

The Company’s wholly-owned subsidiary, Mesa Pharmacy, Inc., provides doctors with an alternative to oral pain medications. Mesa Pharmacy focuses on providing custom compounded non-narcotic, transdermal topical pain medications. These are marketed to industrial health physicians and medical clinics.

Mesa Pharmacy has developed a series of topical creams, in different strengths. The transdermal creams are tailored to patients suffering from long-term pain associated with work place related injuries. Mesa is now licensed to dispense its medications in the states of Arizona, California, Florida, Hawaii, Illinois, Indiana, Nevada, New Mexico, Oklahoma, Texas, Washington, and Wisconsin.

Praxsyn, via subsidiary Mesa Pharmacy, provides a series of formulations that are compounded by using Food and Drug Administration (FDA) approved pain medications formulations to help patients suffering from pain associated with injuries. By way of compounding, a patient can receive medication exactly formulated for his or her needs as well as medical history. 

For the most part, prescriptions are compounded by a pharmacy in Praxsyn’s network, within 24 hours of receipt of the prescription. They are next shipped the following day air, directly to the patient.

Last month, Praxsyn announced that it appointed Kelly Reynolds to the position of CEO and Manager of NexGen Med Solutions, LLC. NexGen is a wholly owned subsidiary of Praxsyn.

NexGen Med Solutions is a billing and collections company. It recently established to enable Praxsyn to manage its accounts receivables in a more cost-effective and efficient manner. The anticipation is that the new subsidiary will provide an integrated alternative to previous billing and collections procedures.

Praxsyn Corp. (PXYN), closed Monday's trading session at $0.64 up 17.43%, on 2,234,849 volume with 96 trades. The average volume for the last 60 days is 998,123 and the stock's 52-week low/high is $0.01/$0.24.

AtheroNova, Inc. (AHRO)

Streetwise Reports, RedChip, FeedBlitz, and UltimatePennyStock reported previously on AtheroNova, Inc. (AHRO), and we also report on the Company, here at the QualityStocks Daily Newsletter.

AtheroNova, Inc. is a biotechnology company headquartered in Irvine, California. Its emphasis is on the discovery, research, development, and licensing of novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans. AtheroNova’s intention is to develop (along with its lead compound AHRO-001) multiple applications for the Company’s patented and patents-pending therapies in market sectors that include Cardiovascular Disease, Stroke, and Peripheral Artery Disease; all of these have been linked to atherosclerosis. AtheroNova lists on the OTC Markets’ OTCQB.

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. AHRO-001 has shown positive results in animal models for regression of plaque. It is undergoing human studies in pursuit of these same successful results. The AHRO delipidization process came about by co-inventors Dr. Giorgio Zadini and Dr. Filiberto Zadini. Their research - covered by AHRO patent applications - dissolves plaques in artery walls so they are removed through normal body processes. AHRO-001 penetrates through the atherosclerotic fibrous cap and, through delipidization, causes fast reduction in the size of the deposits of soft vulnerable plaque in an artery's walls.

AtheroNova is developing AHRO-001 to directly compete with statins that largely lower cholesterol and stabilize plaque. AHRO-001, in preclinical studies, did not show adverse effects, including morbidity or mortality. Additionally, AHRO-001 was well tolerated at high doses. Regarding pre-clinical studies, AtheroNova successfully completed preclinical studies at UCLA and Cedars‐Sinai. In these studies, use of AHRO-001 led to a 95 percent reduction in innominate arterial plaque formation versus the control group.

AtheroNova announced, in December of 2013, achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study goal is to evaluate the safety, tolerability, and pharmacokinetics of AHRO-001 in healthy volunteers.

The clinical study is taking place in Russia with AtheroNova's licensing partner, OOO CardioNova. OOO CardioNova is an operational company in the Russian Federation founded by Maxwell Biotech Group to conduct clinical trials of AHRO-001, seek its approval, and subsequently commercialize it in the territories covered by the license agreement. Maxwell Biotech Group is a development partner and financial resource for biotechnology companies.

In July 2014, AtheroNova announced that its partner, CardioNova, accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. The Phase 1b trial will be a continuation of the AHRO-001 Phase 1 safety trial completed in February 2014, in which patients were dosed with AHRO-001 for up to three weeks. AtheroNova will remain blinded to data from the earlier Phase 1 cohorts until the completion of Phase 1b. At that time the topline data will be presented together in roughly six to eight months.

AtheroNova, Inc. (AHRO), closed Monday's trading session at $0.40, up 14.29%, on 202,313 volume with 45 trades. The average volume for the last 60 days is 40,341 and the stock's 52-week low/high is $0.31/$6.70.

Aeolus Pharmaceuticals, Inc. (AOLS)

TaglichBrothers, Ceocast News, and SmallCapVoice reported previously on Aeolus Pharmaceuticals, Inc. (AOLS), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

OTCQB-listed Aeolus Pharmaceuticals, Inc. is a biotechnology company based in Mission Viejo, California. It is developing compounds to protect against radiological and chemical threats. It is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds, which protect healthy tissue from the damaging effects of radiation. Its first and lead compound is AEOL 10150.
The Company’s strategy is to take advantage of the substantial investment in toxicology, manufacturing, as well as preclinical and clinical studies made by U.S. Government agencies in AEOL 10150 to efficiently develop the compound for use in oncology. AEOL 10150 is undergoing development, with funding by the U.S. Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons.

Aeolus Pharmaceuticals is developing AEOL-10150 as a treatment for the pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and delayed effects of acute radiation exposure (DEARE) under a 5-year contract with BARDA worth up to $118.4MM. BARDA is a division of the U.S. Department of Health and Human Services that manages the advanced development and purchase of medical countermeasures for public health threats.

AEOL 10150 is also being studied by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal tract and by NIH CounterACT as a countermeasure against chlorine gas and sulfur mustard gas exposure.

AEOL 10150’s initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. AEOL 10150 is a broad-spectrum catalytic antioxidant. The specific design of it is to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.

AEOL 10150 was well-tolerated in two human clinical trials. It has also demonstrated statistically significant survival efficacy in multiple Lung-ARS studies in animals. Additionally, AEOL 10150 is now in development for use as a therapeutic and prophylactic drug in cancer patients.

Moreover, Aeolus has designated AEOL 11207 as its second development candidate. Data collected to date suggest that AEOL 11207 may be useful as a potential once-every-other-day oral therapeutic treatment option for central nervous system (CNS) disorders, most probably Parkinson’s disease.

In October, Aeolus Pharmaceuticals announced that data from its recently completed study in non-human primates (NHP) demonstrating that 60 days of treatment with AEOL 10150 improved survival from 25 percent to 50 percent (p=0.042) - doubling survival at 180 days after radiation exposure to the lungs was presented at the 60thAnnual Meeting of the Radiation Research Society. 

The data was presented by Ann Farese of the University of Maryland School of Medicine (UM SOM). This was as part of a presentation on drugs that have shown significant efficacy in animal models of radiation. The presentation of Efficacy Data for AEOL 10150 in multiple studies showed significant survival improvement and tissue protection after radiation exposure to the lungs.

Aeolus Pharmaceuticals, Inc. (AOLS), closed Monday's trading session at $0.2886, up 4.98%, on 29,247 volume with 8 trades. The average volume for the last 60 days is 79,790 and the stock's 52-week low/high is $0.1875/$0.549.


The QualityStocks
Company Corner


Nhale, Inc. (NHLE)

The QualityStocks Daily Newsletter would like to spotlight Nhale, Inc. (NHLE). Today, Nhale, Inc. closed trading at $0.4201, up 10.55%, on 34,019 volume with 26 trades. The stock’s average daily volume over the past 60 days is 14,835, and its 52-week low/high is $0.14/$1.33.

Nhale, Inc. announced it is in talks with a private, Oregon-based company that has marijuana production capabilities, with the intent of growing legal cannabis, if and when the state legalizes recreational marijuana in the upcoming election on Tuesday, November 4. The company under consideration intends to apply for a permit from the state to begin operations on approximately 20 acres of land in western Oregon.

Nhale, Inc. (NHLE) develops and sells leading-edge technology in alignment with its mission to become a recognized, premier innovator in cannabis cultivation, dispensaries, testing and scientific products. Nhale explores innovations that will position the company on the front lines of the marijuana revolution.

Nhale is currently aggressively focused on grow operations in states where cannabis is legal, or soon to be legal, such as Oregon, Alaska and Florida. As an increasing number of states move towards legalization for medical or recreational use, growers are positioned to benefit from economies of scale due to escalating demand. Focusing on candidates in the cultivation space, Nhale is poised grow into a successful, sustainable enterprise through product or company acquisition in this explosive space.

Growpod, Nhale’s self-contained grow environment technology, is one of the company’s products and an entry point into the promising cultivation technology space. Growpod uses “controlled environment agriculture” to optimize plant development, plant quality and production efficiency in all climates and seasons.

Nhale believes innovation produces profitability, especially in growth-stage organizations entering emerging industries. This belief guides Nhale’s strong commitment to develop and commercialize cutting-edge consumer-oriented products primed for rapid commercialization. The company has identified strategic industry partnerships to support this growth objective and to secure an increasing footprint in the booming marijuana market. Disclaimer

Nhale, Inc. Company Blog

Nhale, Inc. News:

NHLE Engages Discussion With Oregon Marijuana Grower in Expectation of State Marijuana Legalization

NHLE Eyeing Acquisition Targets

NHLE Building Prototype for Growpod, the Latest Technology in Modular Grow Systems

Intercept Energy Services, Inc. (IESCF)

The QualityStocks Daily Newsletter would like to spotlight Intercept Energy Services, Inc. (IESCF). Today, Intercept Energy Services, Inc. closed trading at $0.0375, even for the day. The stock’s average daily volume over the past 60 days is 6,792, and its 52-week low/high is $0.0316/$0.09.

Intercept Energy Services, Inc. (IESCF) is an innovative Oilfield Services Firm (OFS) primarily focused on the deployment of its proprietary BIG HEAT frac water heating technology used by oil and gas exploration and production companies operating in Canada and the United States. The company also specializes in unconventional energy extraction and related services such as oil sands processing, oilfield equipment, and oilfield waste disposal and recovery of reusable products from waste.

The BIG HEAT is a patent pending propane-powered system that provides a superior heating method compared to traditional methods used by oil and gas companies and their fracking operations. Equipped with numerous safety shut-offs and little-to-no radiant heat emanating from an encased burner, the BIG HEAT virtually eliminates any possibility of on-site injuries or accidents associated with traditional water heating methods. The technology’s clean, complete and efficient burning capability makes it the most cost effective, safest and environmentally friendly frac water heating system available today.

Committed to providing innovative and efficient products to the oil and gas industry, Intercept Energy also offers an existing line of services and equipment designed that enhance safety, increase efficiency and result in lower costs. The latest addition to Intercept Energy’s portfolio is an Energy Superheater Unit, which is safe to operate, harmless to the well site infrastructure, and preserves environmental integrity.

Tapping into the lucrative $750 billion dollar oil and gas services industry, Intercept Energy has established a clearly defined business plan to deploy additional BIG HEAT units throughout Canada and the United States to follow the fastest route to generating new income, company value and growth. Intercept Energy has the exclusive use of and rights to operate the water heating units in Canada and further in certain areas in the United States. Intercept Energy trades on the OTCQB under ticker symbol “IESCF” and the Toronto Stock Exchange under the ticker symbol “IES.V”. Disclaimer

Intercept Energy Services, Inc. Company Blog

Intercept Energy Services, Inc. News:

Intercept Annual General Meeting Result

Intercept Appoints Keith Morlock as New President and COO

Intercept Announces the Closing of the First Tranche of a Private Placement

Boreal Water Collection, Inc. (BRWC)

The QualityStocks Daily Newsletter would like to spotlight Boreal Water Collection, Inc. (BRWC). Today, Boreal Water Collection, Inc. closed trading at $0.012, up 3.45%, on 12,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 874,661, and its 52-week low/high is $0.0032/$0.03.

Boreal Water Collection, Inc. today announced that the prestigious The Chatwal Hotel (NY) has agreed to begin purchasing its private label bottled water from Boreal's line of customized water products. Boreal will be bottling their private labeled bottled water out of its NY Catskill Mountains plant.

Boreal Water Collection, Inc. (BRWC) is an established water bottler of premium private-labeled bottled water products tailored for each client’s particular need, be it publicity, promotion, marketing, internal use or a specific event. This emphasis on customization and quality has earned Boreal an impressive reputation, evidenced by its prestigious customer base of high-end beverage brands, retailer channels, high-end hotels and restaurant chains such as H&M, Mercedes, W Hotels, Dean & Deluca, Fred Water, Wat-aah, Saks Fifth Ave, Balance Water, NY Quin Hotel, Bouchon Bakery and Princeton University, just to name a few!

Located 90 miles north New York City, Boreal’s plant is only 17 miles from its well-protected source of natural spring water, a pristine and abundant spring source deep inside the heart of the Catskill Mountains. The spring’s exceptional geological and geographical features have created the perfect environment for Boreal’s low-mineral, sodium-free and well-balanced PH water. With exclusive exploitation rights, Boreal has a confirmed volume in excess of thousands of millions of gallons.

Boreal offers a line of award-winning water products, including functional enhanced water, infused water, carbonated water, vitamins enhanced water, flavored still or sparkling, minerals enhanced water, oxygenated water, electrolyte water, distilled water, alkaline water, caffeinated water and natural spring water.

Accommodating this plentiful water supply and range of product offerings, Boreal has established a 75,000-square foot manufacturing facility. Boreal can process a full range of water and bottle types and has the most creative staff for all private labeling needs. The company offers fully integrated turnkey service, made-to-order labeling along with distinctive water bottles. In short, Boreal is a “Boutique Bottler” and is focusing on becoming the leader of this attractive niche of the growing multi-billion dollar bottled water industry. Disclaimer

Boreal Water Collection, Inc. Company Blog

Boreal Water Collection, Inc. News:

The Chatwal Hotel (NY) Agrees to Have Boreal Water Collection Produce Their Private Labeled Bottled Water

Boreal Water Collection, Inc. Announces Engagement of QualityStocks Investor Relations Services

H&M Group (Manhattan) Signs With Boreal Water Collection

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.06, even for the day. The stock’s average daily volume over the past 60 days is 110 and its 52-week low/high is $0.06/$0.60.

Dominovas Energy Corp. today announced the appointment of Emilio De Jesus as a member of its board of directors, effective immediately. De Jesus' appointment expands the board to five directors. De Jesus will be a member and head of the Africa Development committee with specific responsibilities for the continued evolution of Dominovas Energy's political capital in Africa.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Corp. Appoints International Business Professional to Board of Directors

Dominovas Energy and Delphi Sign MOU

Western Standard Energy Corp. (WSEG) Changes Corporate Name To Dominovas Energy Corporation (DNRG)

WRIT Media Group, Inc. (WRIT)

The QualityStocks Daily Newsletter would like to spotlight WRIT Media Group, Inc. (WRIT). Today, WRIT Media Group, Inc. closed trading at $0.0286, up 104.29%, on 701 volume with 2 trades. The stock’s average daily volume over the past 60 days is 53,511, and its 52-week low/high is $0.0107/$0.50.

WRIT Media Group, Inc. (WRIT) is focused on expanding in the digital media industry. The holding company currently operates under two different divisions: content creation via Front Row Networks, and "retro" video gaming via Retro Infinity Inc. and Amiga Games Inc.

The company’s Front Row Networks subsidiary produces, acquires and distributes live concerts in 2D and 3D format for initial worldwide digital broadcast into digitally-enabled movie theaters. In addition to presenting live concerts to massive audiences at lower ticket prices, Front Row Networks will license the content for many different distribution channels and sell merchandize where the live concerts are exhibited. The subsidiary also secures and distributes non-concert alternative theatrical programming and aims to acquire the broadest range of rights for exclusive programming.

Retro Infinity specializes in licensing classic computer and console video game libraries and adapts and republishes the most popular titles for smartphones, modern game consoles, micro-consoles, PCs, and tablets. The company leverages platform and classic game brands, coupled with proprietary technologies, to create new revenue from dormant game libraries.

Amiga Games Inc. shares resources with Retro Infinity to adapt and republish the most popular titles from the Amiga family of computers for smartphones, modern game consoles, micro-consoles, PCs, and tablets. WRIT Media Group leverages the Amiga brand along with game brands of the past and proprietary technologies to create new revenue from classic games that have proven their ability to sell very well.

Together with its subsidiaries, WRIT Media Group is well positioned to benefit from the market growth and increased demand for alternative theatrical, mobile, and interactive content. Disclaimer

WRIT Media Group, Inc. Company Blog

WRIT Media Group, Inc. News:

Retro Infinity Sponsors NASCAR Driver Carlos Contreras' Record-Breaking 99th Career Race

WRIT Media Group (WRIT) CEO Featured in Exclusive QualityStocks Interview

WRIT Media Announces Launch of Online Video Game Point of Sale Platforms

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.42, up 2.46%, on 94,893 volume with 38 trades. The stock’s average daily volume over the past 60 days is 92,523, and its 52-week low/high is $0.15/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc.; MRSA/SA Prototype Achieves over 95% Sensibility in Cultured Headspace

Zenosense, Inc.; Protocol Design -- Lung Cancer Detection Tests

Zenosense, Inc. Update -- MRSA and Lung Cancer Device Development

One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.008, up 6.67%, on 540,000 volume with 5 trades. The stock’s average daily volume over the past 60 days is 743,424, and its 52-week low/high is $0.0033/$2.6923.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

The One World Doll Project Announces Financing Relationship With New York Hedge Fund, Blackbridge Capital

One World Holdings, Inc. Announces Engagement of QualityStocks Investor Relations Services

The One World Doll Project Announces New Online Distribution With Toys"R"Us®


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Real Pennies




Stock Analyzer

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251